Search clinical trials for: GW679769

Total 24 results

GlaxoSmithKline

Completed

Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia

Insomnia | Sleep Initiation and Maintenance Disorders

United States, Canada
GlaxoSmithKline

Completed

GW679769 In Fibromyalgia

Depressive Disorder | Depression | Fibromyalgia
GlaxoSmithKline

Completed

Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia

Insomnia | Sleep Initiation and Maintenance Disorders

United States
GlaxoSmithKline

Completed

Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Belgium, Peru, Argentina, Chile, Costa Rica, Slovakia, Italy, Germany, Poland, Spain, Sweden
GlaxoSmithKline

Completed

A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

Nausea and Vomiting, Chemotherapy-Induced

Finland, Czechia, Argentina, Belgium, Philippines, Taiwan, Korea, Republic of, Bulgaria, Spain, Ireland, Thailand, Greece, Pakistan, Slovakia, Italy, Romania, Poland, Hungary, Ukraine, Croatia, Malaysia, India
GlaxoSmithKline

Completed

Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment

Vomiting

United States
GlaxoSmithKline

Completed

Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia

Insomnia | Sleep Initiation and Maintenance Disorders

United States, Germany, France
GlaxoSmithKline

Completed

A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia

Sleep Initiation and Maintenance Disorders

United States
GlaxoSmithKline

Terminated

Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients

Overactive Bladder | Incontinence, Urinary and Urinary Bladder, Overactive

United States
GlaxoSmithKline

Completed

Study Of GW679769 In Major Depressive Disorder

Depressive Disorder, Major | Major Depressive Disorder (MDD)

United States, Canada
GlaxoSmithKline

Completed

Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment

Vomiting

United States
GlaxoSmithKline

Completed

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder

Overactive Bladder | Incontinence, Urinary and Urinary Bladder, Overactive

United States, Canada
GlaxoSmithKline

Completed

fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder

Social Anxiety Disorder

United States
GlaxoSmithKline

Completed

Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

Nausea and Vomiting, Postoperative

United States, Hong Kong, Ireland, France, Philippines, Germany, Hungary, Thailand, Canada, Pakistan, United Kingdom
GlaxoSmithKline

Completed

An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia

Nonulcer Dyspepsia

Belgium
GlaxoSmithKline

Completed

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

Nausea | Vomiting | Nausea and Vomiting, Chemotherapy-Induced

United States, Germany, Bulgaria, Hungary, Philippines, Russian Federation, Taiwan, Korea, Republic of, Belgium, Denmark, Hong Kong, Slovakia, South Africa, Spain, Ireland, Latvia, Thailand, Italy, United Kingdom, Argentina, Aus... and more
GlaxoSmithKline

Completed

Post-Operative Nausea And Vomiting Study In Female Patients

Postoperative Nausea and Vomiting | Nausea and Vomiting, Postoperative

United States, Spain, Philippines, Israel, Hong Kong, Thailand, United Kingdom, Hungary, Slovenia, Norway, Denmark
Pharmos

Completed

Dexanabinol in Severe Traumatic Brain Injury

Traumatic Brain Injury
GlaxoSmithKline

Completed

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

Nausea and Vomiting, Chemotherapy-Induced

United States
GlaxoSmithKline

Completed

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

Nausea and Vomiting, Chemotherapy-Induced

United States
GlaxoSmithKline

Terminated

Cyclophosphamide Drug Interaction Study In Cancer Patients

Nausea and Vomiting, Chemotherapy-Induced

United States, Sweden, New Zealand
GlaxoSmithKline

Completed

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

Chemotherapy-Induced Nausea and Vomiting | Nausea and Vomiting, Chemotherapy-Induced

Taiwan, United States, Germany, Russian Federation, Spain, Ireland, Thailand, Hong Kong, Mexico, Philippines, Austria, Chile, Greece, Poland, Canada, Czech Republic, United Kingdom, Hungary, Pakistan, Slovakia, Singapore, Portugal, ... and more
GlaxoSmithKline

Completed

A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

Nausea and Vomiting, Chemotherapy-Induced

United States
GlaxoSmithKline

Completed

Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy

Nausea and Vomiting | Chemotherapy-Induced

Taiwan, Belgium, Singapore, Netherlands, Mexico, Slovakia, Italy, Philippines, Austria, Chile, Romania, Poland, Czech Republic, Hungary, Pakistan, Croatia, Peru, Argentina, Hong Kong

Search clinical trials for: GW679769

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations